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Abstract
Inflammatory bowel diseases (IBDs), particularly 
Crohn’s disease (CD) and ulcerative colitis (UC), 
are associated with a variety of extra-intestinal 
manifestations (EIMs). About 36% of IBD patients have 
at least one EIM, which most frequently affect the joints, 
skin, eyes and the biliary tract. The EIMs associated 
with IBD have a negative impact on patients with UC 
and CD, and the resolution of most of them parallels 
that of the active IBD in terms of timing and required 
therapy; however, the clinical course of EIMs such as 
axial arthritis, pyoderma gangrenosum, uveitis, and 
primary sclerosing cholangitis is independent of IBD 
activity. The peripheral and axial arthritis associated 
with IBD have traditionally been treated with simple 
analgesics, non-steroidal anti-inflammatory drugs, 
steroids, sulfasalazine, methotrexate, local steroid 
injections and physiotherapy, but the introduction of 
biological response modifiers such as tumor necrosis 
factor-α blockers, has led to further improvements.
© 2009 The WJG Press and Baishideng. All rights reserved.
Key words: Anti-tumor necrosis factor antagonists; 
Inflammatory bowel disease; Treatment; Arthropathies
Peer reviewer: Abraham R Eliakim, Professor, Gastro-
enterology, Rambam Medical Center, Technion School of 
Medicine, PO Box 9602, Haifa 31096, Israel
Atzeni F, Ardizzone S, Bertani L, Antivalle M, Batticciotto A, 
Sarzi-Puttini P. Combined therapeutic approach: Inflammatory 
bowel diseases and peripheral or axial arthritis. World J 
Gastroenterol 2009; 15(20): 2469-2471  Available from: URL: 
http://www.wjgnet.com/1007-9327/15/2469.asp  DOI: http://
dx.doi.org/10.3748/wjg.15.2469
INTRODUCTION
Inflammatory bowel diseases (IBD), particularly Crohn’s 
disease (CD) and ulcerative colitis (UC), are associated 
with a variety of  extra-intestinal manifestations (EIMs)[1]. 
About 36% of  IBD patients have at least one EIM[2], 
and these have a negative impact on UC and CD 
patients. The most frequent EIMs affect the joints, 
skin, eyes and the biliary tract[3], but others give rise to 
small bowel dysfunctions (cholelithiasis, nephrolithiasis 
and obstructive uropathy) or are non-specific disorders 
(osteoporosis, hepatobiliary disease and amyloidosis)[1,2]. 
Although the association between EIMs and IBD has 
long been recognized, the underlying pathogenetic 
factors remain unclear. The reported incidence of  
peripheral and axial arthropathies ranges from 4% to 
23%[4,5].
The Oxford group distinguished two types of  
peripheral arthropathy on the basis of  their articular 
involvement[4]: (1) Type Ⅰ is a large joint pauci-articular 
arthropathy that mainly affects the ankles, knees, hips, 
wrists, elbows and shoulders; is usually acute and self-
limiting; occurs at times of  IBD activity; and leaves no 
permanent joint damage. (2) Type Ⅱ is a polyarticular 
arthropathy that mainly affects the small joints of  both 
hands symmetrically; is characterised by pain that usually 
persists for months or years; and is largely independent 
of  IBD activity.
Axial arthritis includes sacroiliitis and ankylosing 
spondylitis (AS)[5]: (1) Sacroiilitis may be asymptomatic or 
symptomatic[6]; asymptomatic sacroiilitis is common and 
up to 50% of  CD patients show abnormal radiographic 
findings; symptomatic sacroiliitis is characterised by pain 
in the pelvis after rest, which improves with movement, 
and discomfort in the sacroiliac joints during bilateral 
pressure on the pelvic brim. (2) AS is characterised 
by persistent low back pain beginning before the age 
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of  30 years, and its clinical diagnosis is supported by 
characteristic radiological changes for which magnetic 
resonance imaging is the diagnostic tool of  choice[7,8]. 
Although HLA B-27 is over-represented in IBD-related 
axial arthritis, it is of  no diagnostic value[9].
THERAPEUTIC APPROACHES TO IBD 
AND ARTHROPATHIES
The treatment of  IBD-associated arthropathies is almost 
entirely based on extrapolations from other forms of  
arthritis.
In the case of  type Ⅰ peripheral arthritis, treatment 
should concentrate on the active disease and include 
steroids, immunomodulators and anti-tumor necrosis 
factor-α (TNF-α)[10-12]; however, all forms of  IBD-
related arthritis seem to be treated with sulfasalazine 
(SSZ) despite the lack of  supportive evidence[13]. The 
symptoms can be relieved using simple analgesics, rest 
and physiotherapy. Non-steroidal anti-inflammatory 
drugs may aggravate the underlying colitis[14], but the 
findings of  a randomised study regarding the safety of  
celecoxib[15] indicate that its short-term use (< 2 wk) does 
not exacerbate colitis. A local steroid injection into the 
affected joints provides rapid but only temporary relief.
The treatment of  AS should include intensive 
physiotherapy, together with the administration of  
disease-modifying drugs such as SSZ and methotrexate. 
However, since TNF-α has been shown to play a key 
role in the pathogenesis of  AS and IBD, the treatment 
of  this manifestation has changed[16].
The advent of  biological response modifiers such 
as TNF-α blockers has improved the treatment of  IBD 
and its associated peripheral and axial arthritides, and 
their safety and efficacy have been clearly established 
in the case of  AS-related peripheral arthritis. IBD 
patients failing on immunomodulation therapy used 
to be recommended surgery, but are now treated with 
biological agents.
Table 1 lists the currently used treatments for IBD-
related arthropathies.
Anti-TNF antagonists
Infliximab is a chimeric IgG1 monoclonal antibody to 
TNF and represents a significant advance in the treatment 
of  IBD with or without associated arthropathies[17]. There 
are anecdotal accounts of  infliximab rapidly improving 
peripheral arthritis in IBD patients. Ellman et al[18] have 
reported the findings of  an open-label study in which 
four patients with treatment-refractory peripheral arthritis 
responded to treatment with infliximab 5 mg/kg and, 
subsequently, a large-scale prospective, open-label trial 
demonstrated an improvement in peripheral arthritis 
in IBD patients who had previously been refractory 
to corticosteroids, 6-mercaptopurine, azathioprine 
or methotrexate [19]. Another small open-label study 
documented an improvement in the arthralgias of  
seven out of  11 IBD patients after a single infusion of  
infliximab 5 mg/kg[20].
On the basis of  the available data, it seems that most 
IBD patients with active intestinal inflammation and 
concurrent peripheral arthritis are likely to experience 
an improvement in their joint symptoms upon receiving 
infliximab.
Adalimumab is a subcutaneously self-administered 
fully human monoclonal antibody against TNF-α that 
is efficacious in inducing and maintaining remission in 
patients with moderate-to-severe CD[21], but there are no 
published data concerning its efficacy in patients with 
concomitant IBD and arthritis.
Infliximab, etanercept and adalimumab have all been 
found to have positive short- and long-term effects on 
disease signs and symptoms in AS patients[22,23]. Braun 
et al[24] analysed the data from nine trials of  anti-TNF 
agents (seven placebo-controlled and two open-label 
studies) and found that the treatment is efficacious in 
treating AS and IBD, and that the onset and flare of  
IBD are infrequent events in AS patients receiving anti-
TNF therapy. Infliximab (but not etanercept) largely 
prevents IBD and AS activity but more data are required 
in the case of  adalimumab.
The efficacy of  adalimumab in the treatment of  
AS is mainly supported by the findings of  the recent 
multicentre, randomized, double-blind and placebo-
controlled trial conducted by van der Heijde et al[25] who 
observed that the response of  most of  the patients 
treated with adalimumab was better than that observed 
in the patients treated with placebo.
No published studies have yet addressed the effect 
of  switching from infliximab to adalimumab in patients 
with CD-related spondyloarthropathy. We have recently 
evaluated the clinical response to adalimumab of  19 
CD patients with associated spondyloarthritis who 
discontinued infliximab because of  intolerance or loss 
of  efficacy, and found that it successfully controlled both 
articular and intestinal disease activity[26].
In conclusion, about 36% of  IBD patients have at 
least one EIM, especially articular involvement, and the 
introduction of  anti-TNF therapy has improved the 
treatment of  both. In particular, the subgroup of  Crohn’s 
disease patients with arthritic problems could be the one 
in which anti-TNF agents are most indicated.
Table 1  Therapy of spondyloarthropathies
Therapy
Standard initial therapy NSAIDs and anti-COX-2
Physical activity
Local steroids
Second line therapy Sulfasalazine
Methotrexate
Gold
Others (penicillamine, etc) 
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